Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Royalty Pharma paid $100 million for a piece of money that a blood-disorder medicine might make if it gets approved by the FDA next year. This shows Royalty Pharma believes in the drug's chances, which is a vote of confidence in that medicine.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.